Advances in Diagnostics and Treatment of Functional Neurological Disorders: Neurogenomics, Neuromodulation and Machine-Learning

143.7K
views
212
authors
26
articles
Cover image for research topic "Advances in Diagnostics and Treatment of Functional Neurological Disorders: Neurogenomics, Neuromodulation and Machine-Learning"
Editors
4
Impact
Loading...

Background: Deep brain stimulation (DBS) is a typical intervention treating drug-refractory dystonia. Currently, the selection of the better target, the GPi or STN, is debatable. The outcomes of DBS treating dystonia classified by body distribution and etiology is also a popular question.

Objective: To comprehensively compare the efficacy, quality of life, mood, and adverse effects (AEs) of GPi-DBS vs. STN-DBS in dystonia as well as in specific types of dystonia classified by body distribution and etiology.

Methods: PubMed, Embase, the Cochrane Library, and Google Scholar were searched to identify studies of GPi-DBS and STN-DBS in populations with dystonia. The efficacy, quality of life, mood, and adverse effects were quantitatively compared. Meta-regression analyses were also performed. This analysis has been registered in PROSPERO under the number CRD42020146145.

Results: Thirty five studies were included in the main analysis, in which 319 patients underwent GPI-DBS and 113 patients underwent STN-DBS. The average follow-up duration was 12.48 months (range, 3–49 months). The GPI and STN groups were equivalent in terms of efficacy, quality of life, mood, and occurrence of AEs. The focal group demonstrated significantly better disability symptom improvement (P = 0.012) than the segmental and generalized groups but showed less SF-36 enhancement than the segmental group (P < 0.001). The primary groups exhibited significantly better movement and disability symptom improvements than the secondary non-hereditary group (P < 0.005), which demonstrated only disability symptom improvement compared with the secondary hereditary group (P < 0.005). The primary hereditary and idiopathic groups had a significantly lower frequency of AEs than the secondary non-hereditary group (P < 0.005). The correlation between disability symptom improvement and movement symptom improvement was also significant (P < 0.05).

Conclusion: GPi-DBS and STN-DBS were both safe and resulted in excellent improvement in efficacy and quality of life in patients with dystonia. Compared with patients with segmental dystonia, patients with focal dystonia demonstrated better improvement in dystonia symptoms but less enhancement of quality of life. Those with primary dystonia had a better response to DBS in terms of efficacy than those with secondary dystonia. Patients who exhibit a significant improvement in movement symptoms might also exhibit excellent improvement in disability symptoms.

14,643 views
42 citations
12,157 views
71 citations
10,637 views
22 citations
Changes in the levels of TNFα, IL-1β, and IL-6 in the maternal serum and fetal brain at 5 h following LPS treatment in the WT and TLR4−/− mice. (A) The effect of PBS and LPS treatment on the levels of TNFα, IL-1β, and IL-6 in the maternal serum in pregnant WT and TLR4−/− mice (n = 5). (B) The significant effect of LPS, independent of TLR4−/−, on the concentration of TNFα in the maternal serum in the combined PBS and LPS groups (n = 10). (C) Effect of PBS and LPS treatment on the levels of TNFα, IL-1β, and IL-6 in the fetal brain in the WT and TLR4−/− offspring (n = 5). (D) LPS independently affected the concentrations of TNFα on the fetal brain in the combined PBS and LPS groups (n = 10). (E) Significant effect of TLR4−/−, independent of LPS treatment, on the level of IL-1β on the fetal brain in the combined WT and KO groups (n = 10). The values are expressed as the means ± SEMs. “Interaction” indicates an effect of LPS in the TLR4−/− vs. WT mice; ns, not significant, *P < 0.05; **P < 0.01; and ***P < 0.001.
8,115 views
34 citations
Fetching...